Portola Pharmaceuticals Announces Full Results From ANNEXA-4 Study Of Factor Xa Inhibitor Reversal Agent Andexxa In Patients With Life-Threatening Bleeding; Achieved 'Excellent Or Good' Homeostasis In 82% Of Patients